Abstract
A major conceptual breakthrough in cell signaling has been the finding of EV as new biomarker shuttles in body fluids. Now, one of the major challenges in using these nanometer-sized biological entities as diagnostic marker is the development of translational methodologies to profile them. SPR offers a promising label-free and real time platform with a high potential for biomarker detection. Therefore, we aimed to develop a uniform SPR methodology to detect specific surface markers on EV derived from patient with CHD. EVs having an approximate size range between 30 and 100 nm (similar to 48.5%) and 100-300 nm (similar to 51.5%) were successfully isolated. The biomarker profile of EV was verified using immunogold labeling, ELISA and SPR. Using SPR, we demonstrated an increased binding of EV derived from patients with CHD to anti-ICAM-1 antibodies as compared to EV from healthy donors. Our current findings open up novel opportunities for in-depth and label-free investigation of EV. (C) 2017 The Authors. Published by Elsevier Inc.
Original language | English |
---|---|
Pages (from-to) | 1663-1671 |
Number of pages | 9 |
Journal | Nanomedicine-Nanotechnology Biology and Medicine |
Volume | 13 |
Issue number | 5 |
DOIs | |
Publication status | Published - Jul 2017 |
Keywords
- Biosensor
- Extracellular vesicles
- Inflammation
- Cardiovascular disease
- Endothelial cells
- Biomarkers
- EXOSOMES
- DISEASE
- ADHESION
- STROKE
- RISK